Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
1. Silexion selects AMS for Phase 2/3 trials of SIL204. 2. SIL204 shows 97% inhibition rates in KRAS-driven cancer models. 3. Regulatory submissions expected in Q4 2025 and Q1 2026. 4. Trials planned to start in H1 2026, targeting pancreatic cancer. 5. AMS brings 28 years of oncology expertise to Silexion.